Irene Braña
Hebron University(PS)Vall d'Hebron Institut de Recerca(ES)Vall d'Hebron Hospital Universitari(ES)Vall d'Hebron Institute of Oncology(ES)Vall d'Hebron Institute of Oncology
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, PI3K/AKT/mTOR signaling in cancer, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Immunotherapy and Immune Responses
Most-Cited Works
- → PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma(2018)1,358 cited
- → Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial(2019)582 cited
- → Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study(2022)450 cited
- → Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC(2018)306 cited
- → Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy(2018)263 cited
- → LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy